Drug Interaction Report

MONITOR: Coadministration of iptacopan may decrease the exposure of CYP450 3A4 substrates, which may reduce their clinical efficacy. According to in vitro studies, iptacopan has potential for induction of the CYP450 3A4 isoenzyme. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index. However, clinical data evaluating the interaction are not available.

MANAGEMENT: Caution and clinical monitoring are advised if iptacopan is to be used in combination with substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for the concomitant medication should also be consulted to assess the benefits versus risks of coadministration with CYP450 3A4 inducers and for any dosage adjustments that may be required.

GENERALLY AVOID: Acute ethanol ingestion may potentiate the CNS effects of many benzodiazepines. Tolerance may develop with chronic ethanol use. The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition. Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.

MANAGEMENT: Patients should be advised to avoid alcohol during benzodiazepine therapy.